Cannabics Pharmaceuticals Inc. (CNBX) Attends 31st Annual ROTH Conference
Cannabics Pharmaceuticals (OTCQB: CNBX) is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer therapies that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, visit the company’s website at www.cannabics.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that…







